Radiation Toxicity - Pipeline Review, H1 2017

  • ID: 4239830
  • Drug Pipelines
  • 202 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Angion Biomedica Corp
  • Cellphire Inc
  • Genzyme Corp
  • Meabco A/S
  • PharmaIN Corp
  • RxBio Inc
  • MORE
Radiation Toxicity - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Radiation Toxicity - Pipeline Review, H1 2017, provides an overview of the Radiation Toxicity (Toxicology) pipeline landscape.

Radiation Toxicity (also known as radiation sickness) is an acute illness caused by irradiation of the entire body by a high dose of penetrating radiation in a very short period of time (usually a matter of minutes). The major cause of this syndrome is depletion of immature parenchymal stem cells in specific tissues. Symptoms include bleeding from the nose, mouth, gums, and rectum, bloody stool, bruising, confusion, dehydration, diarrhea, fainting and fatigue

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Radiation Toxicity - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Radiation Toxicity (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Radiation Toxicity (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 5, 7, 46, 9 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Radiation Toxicity (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Radiation Toxicity (Toxicology).
- The pipeline guide reviews pipeline therapeutics for Radiation Toxicity (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Radiation Toxicity (Toxicology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Radiation Toxicity (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Radiation Toxicity (Toxicology)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Radiation Toxicity (Toxicology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Radiation Toxicity (Toxicology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Angion Biomedica Corp
  • Cellphire Inc
  • Genzyme Corp
  • Meabco A/S
  • PharmaIN Corp
  • RxBio Inc
  • MORE
Introduction

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Overview

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Companies Involved in Therapeutics Development

Aeolus Pharmaceuticals Inc

Angion Biomedica Corp

Atox Bio Ltd

BCN Biosciences LLC

Bolder Biotechnology Inc

Cellerant Therapeutics Inc

Cellphire Inc

Chrysalis BioTherapeutics Inc

Cleveland BioLabs Inc

Daiichi Sankyo Company Ltd

FirstString Research Inc

Foresee Pharmaceuticals LLC

Galera Therapeutics Inc

Genzyme Corp

GNI Group Ltd

Humanetics Corp

Insys Therapeutics Inc

Meabco A/S

Neumedicines Inc

Nohla Therapeutics Inc

Onconova Therapeutics Inc

Original BioMedicals Co Ltd

PharmaIN Corp

Pluristem Therapeutics Inc

RDD Pharma Ltd

Reata Pharmaceuticals Inc

RedHill Biopharma Ltd

RxBio Inc

Shuttle Pharmaceuticals LLC

SK Chemicals Co Ltd

Soligenix Inc

Synedgen Inc

Tonix Pharmaceuticals Holding Corp

TSRL Inc

viDA Therapeutics Inc

Windtree Therapeutics Inc

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Drug Profiles

(levocetirizine dihydrochloride + montelukast sodium) - Drug Profile

A-02 - Drug Profile

AB-103 - Drug Profile

ABC-294640 - Drug Profile

AEOL-10171 - Drug Profile

Aerosurf - Drug Profile

amifostine - Drug Profile

amifostine - Drug Profile

AVMOC-001 - Drug Profile

BB-3 - Drug Profile

BBT-007 - Drug Profile

BBT-015 - Drug Profile

BBT-018 - Drug Profile

BBT-059 - Drug Profile

BCN-057 - Drug Profile

BIO-300 - Drug Profile

BMX-001 - Drug Profile

BPC-2 - Drug Profile

C-2E2 - Drug Profile

C-2E5 - Drug Profile

Cell Therapy for Acute Radiation Syndrome - Drug Profile

cerium oxide - Drug Profile

CLT-009 - Drug Profile

Des-Asp Angiotensin 1 - Drug Profile

DG-3 - Drug Profile

entolimod - Drug Profile

EWA-001 - Drug Profile

Fibrinoplate-S - Drug Profile

FP-045 - Drug Profile

Granexin - Drug Profile

HSJ-0017 - Drug Profile

JP4-039 - Drug Profile

LGM-2605 - Drug Profile

m-2A2 - Drug Profile

MDY-1001 - Drug Profile

molgramostim - Drug Profile

NAS-911 - Drug Profile

NMIL-121 - Drug Profile

omaveloxolone - Drug Profile

ondansetron hydrochloride - Drug Profile

ondansetron hydrochloride CR - Drug Profile

Peptide to Agonize GHSR for Acute Ischemic Stroke, Acute Radiation Syndrome and Sepsis - Drug Profile

pirfenidone - Drug Profile

PLXR-18 - Drug Profile

Preimplantation Factor - Drug Profile

QR-205 - Drug Profile

RDD-2007 - Drug Profile

recilisib sodium - Drug Profile

Recombinant Protein C for Sepsis, Stroke and Radiation Toxicity - Drug Profile

Recombinant Protein for Acute Kidney Injury, Acute Radiation Syndrome, Inflammatory Bowel Disease, Ischemic Organ Injury, and Sepsis - Drug Profile

Recombinant Protein to Activate FGF-4 for Radiation Injury - Drug Profile

Recombinant Protein to Activate FGF-7 for Radiation Injury - Drug Profile

RP-239X - Drug Profile

RS-9 - Drug Profile

rusalatide acetate - Drug Profile

Rx-100 - Drug Profile

sargramostim - Drug Profile

SGX-201 - Drug Profile

SGX-202 - Drug Profile

SKI-2162 - Drug Profile

Small Molecule for Prostate Cancer, Asthma and Radiation Injury - Drug Profile

Small Molecule for Radiation Toxicity - Drug Profile

Small Molecule for Radiation Toxicity 1 - Drug Profile

Small Molecule to Antagonize Adenosine A2A Receptor for Radiation Dermatitis - Drug Profile

Small Molecules to Inhibit NO Synthase for Toxicology, Metabolic and Dermatology - Drug Profile

SP-3001 - Drug Profile

ST-266 - Drug Profile

ST-7 - Drug Profile

SY-513 - Drug Profile

SYGN-305 - Drug Profile

SYGN-399 - Drug Profile

Thrombosomes - Drug Profile

TNX-701 - Drug Profile

TPO-7630 - Drug Profile

TPO-7640 - Drug Profile

VEDA-1209 - Drug Profile

VTI-1000 Series - Drug Profile

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1

Number of Products under Development by Companies, H1

Number of Products under Development by Companies, H1 2017 (Contd..1), H1

Number of Products under Development by Companies, H1 2017 (Contd..2), H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Companies, H1 2017 (Contd..1), H1

Products under Development by Companies, H1 2017 (Contd..2), H1

Products under Development by Companies, H1 2017 (Contd..3), H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Target, H1 2017 (Contd..1), H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Aeolus Pharmaceuticals Inc, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Angion Biomedica Corp, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Atox Bio Ltd, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by BCN Biosciences LLC, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Bolder Biotechnology Inc, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellerant Therapeutics Inc, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cellphire Inc, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Chrysalis BioTherapeutics Inc, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Cleveland BioLabs Inc, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Daiichi Sankyo Company Ltd, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by FirstString Research Inc, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Foresee Pharmaceuticals LLC, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Galera Therapeutics Inc, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Genzyme Corp, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by GNI Group Ltd, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Humanetics Corp, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Insys Therapeutics Inc, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Meabco A/S, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Neumedicines Inc, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Nohla Therapeutics Inc, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Onconova Therapeutics Inc, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Original BioMedicals Co Ltd, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by PharmaIN Corp, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Pluristem Therapeutics Inc, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RDD Pharma Ltd, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Reata Pharmaceuticals Inc, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RedHill Biopharma Ltd, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by RxBio Inc, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Shuttle Pharmaceuticals LLC, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by SK Chemicals Co Ltd, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Soligenix Inc, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Synedgen Inc, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Tonix Pharmaceuticals Holding Corp, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by TSRL Inc, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by viDA Therapeutics Inc, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline by Windtree Therapeutics Inc, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H1 2017 (Contd..1), H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Dormant Projects, H1 2017 (Contd..2), H1

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Discontinued Products, H1

List of Figures:

Number of Products under Development for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Number of Products by Top 10 Targets, H1

Number of Products by Stage and Top 10 Targets, H1

Number of Products by Top 10 Mechanism of Actions, H1

Number of Products by Stage and Top 10 Mechanism of Actions, H1

Number of Products by Top 10 Routes of Administration, H1

Number of Products by Stage and Top 10 Routes of Administration, H1

Number of Products by Top 10 Molecule Types, H1

Number of Products by Stage and Top 10 Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Aeolus Pharmaceuticals Inc
  • Angion Biomedica Corp
  • Atox Bio Ltd
  • BCN Biosciences LLC
  • Bolder Biotechnology Inc
  • Cellerant Therapeutics Inc
  • Cellphire Inc
  • Chrysalis BioTherapeutics Inc
  • Cleveland BioLabs Inc
  • Daiichi Sankyo Company Ltd
  • FirstString Research Inc
  • Foresee Pharmaceuticals LLC
  • Galera Therapeutics Inc
  • Genzyme Corp
  • GNI Group Ltd
  • Humanetics Corp
  • Insys Therapeutics Inc
  • Meabco A/S
  • Neumedicines Inc
  • Nohla Therapeutics Inc
  • Onconova Therapeutics Inc
  • Original BioMedicals Co Ltd
  • PharmaIN Corp
  • Pluristem Therapeutics Inc
  • RDD Pharma Ltd
  • Reata Pharmaceuticals Inc
  • RedHill Biopharma Ltd
  • RxBio Inc
  • Shuttle Pharmaceuticals LLC
  • SK Chemicals Co Ltd
  • Soligenix Inc
  • Synedgen Inc
  • Tonix Pharmaceuticals Holding Corp
  • TSRL Inc
  • viDA Therapeutics Inc
  • Windtree Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll